Effects of age and ethnicity on the link between APOE epsilon4 and Alzheimer disease
Shadlen, M.F.
JAMA 279(8): 581; Author Reply 581-2
1998
ISSN/ISBN: 0098-7484 PMID: 9486747 Document Number: 489354
Document emailed within 1 workday
Related Documents
Alvarez, X.A.; Mouzo, R.; Pichel, V.; Pérez, P.; Laredo, M.; Fernández-Novoa, L.; Corzo, L.; Zas, R.; Alcaraz, M.; Secades, J.J.; Lozano, R.; Cacabelos, R. 1999: Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion Methods and Findings in Experimental and Clinical Pharmacology 21(9): 633-644Barker, W.; Harwood, D.; Duara, R.; Mullan, M.; Fallin, D.; Hyslop, P.S.; Rogaeva, E.; Song, Y. 1998: The APOE-epsilon4 allele and Alzheimer disease among African Americans, Hispanics, and whites JAMA 280(19): 1661-2; author reply 1663
Babić, T.; Mahović Lakusić, D.; Sertić, J.; Petrovecki, M.; Stavljenić-Rukavina, A. 2004: ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study Collegium Antropologicum 28(1): 199-204
Coon, K.D.; Myers, A.J.; Craig, D.W.; Webster, J.A.; Pearson, J.V.; Lince, D.Hu.; Zismann, V.L.; Beach, T.G.; Leung, D.; Bryden, L.; Halperin, R.F.; Marlowe, L.; Kaleem, M.; Walker, D.G.; Ravid, R.; Heward, C.B.; Rogers, J.; Papassotiropoulos, A.; Reiman, E.M.; Hardy, J.; Stephan, D.A. 2007: A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease Journal of Clinical Psychiatry 68(4): 613-618
Mauri, M.; Sinforiani, E.; Bono, G.; Cittadella, R.; Quattrone, A.; Boller, F.ço.; Nappi, G. 2006: Interaction between Apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's disease and Mild Cognitive Impairment Functional Neurology 21(4): 223-228
Gillen, T.E.; Gregg, K.M.; Yuan, H.; Kurth, M.C.; Krishnan, K.R. 2001: Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease Psychopharmacology Bulletin 35(2): 83-96
Vinogradova, S.V. 2006: The role of epsilon 2/epsilon 3/epsilon 4 polymorphism of the apolipoprotein e gene in the development of dislipoproteinemia and its influence on the efficacy of the hypolipidemic therapy Tsitologiia i Genetika 40(6): 59-72
Te Velde, A.A.; Rousset, F.; Peronne, C.; De Vries, J.E.; Figdor, C.G. 1990: IFN-alpha and IFN-gamma have different regulatory effects on IL-4-induced membrane expression of Fc epsilon RIIb and release of soluble Fc epsilon RIIb by human monocytes Journal of Immunology 144(8): 3052-3059
Klepak, P.B. 1989: Study of Alzheimer's and aluminum link flawed American Pharmacy 29(10): 6
Mackell, J.A.; Ferris, S.H.; Mohs, R.; Schneider, L.; Galasko, D.; Whitehouse, P.; Schmitt, F.; Sano, M.; Thal, L.J. 1997: Multicenter evaluation of new instruments for Alzheimer's disease clinical trials: summary of results. The Alzheimer's Disease Cooperative Study Alzheimer Disease and Associated Disorders 11 Suppl. 2: S65-S69
Morris, J.C.; Edland, S.; Clark, C.; Galasko, D.; Koss, E.; Mohs, R.; van Belle, G.; Fillenbaum, G.; Heyman, A. 1993: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease Neurology 43(12): 2457-2465
Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Takamaru, Y.; Sasaki, N.; Yoshida, T.; Hatakeyama, Y.; Fuji, N.; Takahata, N. 1997: Recent advances in Alzheimer's disease research--amyloid precursor protein trafficking, processing, and mutations in Alzheimer's disease linked genes Hokkaido Journal of Medical Science 72(1): 3-11
Morris, J.C.; Mohs, R.C.; Rogers, H.; Fillenbaum, G.; Heyman, A. 1988: Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease Psychopharmacology Bulletin 24(4): 641-652
Miyakawa, T. 1988: Brain pathology in Alzheimer's disease. Ultrastructure of amyloid fibrils in Alzheimer's disease and Down's syndrome Nihon Rinsho. Japanese Journal of Clinical Medicine 46(7): 1471-1474
Szpak, G.M.; Lechowicz, W.; Lewandowska, E.; Bertrand, E.; Wierzba-Bobrowicz, T.; Gwiazda, E.; Schmidt-Sidor, B.; Dymecki, J. 2001: Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study Folia Neuropathologica 39(3): 181-192
Crook, T.; Petrie, W.; Wells, C.; Massari, D.C. 1992: Effects of phosphatidylserine in Alzheimer's disease Psychopharmacology Bulletin 28(1): 61-66
Bufill, E.; Blesa, R. 2006: Alzheimer's disease and brain evolution: is Alzheimer's disease an example of antagonistic pleiotropy? Revista de Neurologia 42(1): 25-33
Bradley, R.J.; Edge, M.T.; Freeman, A.M. 1991: The effects of cholinergic preparations in Alzheimer's disease Farmakologiia i Toksikologiia 54(3): 4-10
Mauri, M.C.; Bravin, S.; Fabiano, L.; Invernizzi, G. 1995: Effects of psychopathological components of the onset of Alzheimer's disease Minerva Psichiatrica 36(4): 203-207
Murayama, K.; Sugawara, T.; Hiraga, E.; Ogawa, H. 1983: Quantitation of the epsilon-(gamma-glutamyl)lysine cross-link using a high-speed amino acid analyzer without purification of the dipeptide. Application to enzymatic digested mixtures of keratin and the membranous fraction of human stratum corneum Journal of Chromatography 274: 63-73